For patients with advanced cancer who have exhausted all standard therapeutic options, the medical journey often reaches a crossroads where the only remaining hope lies in “off-label” apply—prescribing a drug for a purpose or patient group it was not officially approved for. While this practice is common in oncology, it has long operated in a grey area of clinical intuition and high risk. New data from a decade-long effort suggests that a prospective evaluation of genomics-guided off-label treatment can transform this gamble into a structured, evidence-based strategy.
The Drug Rediscovery Protocol (DRUP) has spent the last nine years testing this precision approach, providing off-label treatment opportunities to more than 1,600 patients with advanced cancers. By matching the genetic mutations of a patient’s tumor to existing drugs approved for other cancers, the protocol sought to move beyond the traditional “one-size-fits-all” histology approach, where treatment is based solely on where the cancer started in the body.
The results highlight a complex reality: while overall activity across all cohorts was modest, the strategy delivered profound, durable benefits for a specific subset of patients. Across stage 1 and 2 cohorts, 34.9% of patients experienced a clinical benefit, with 15.7% achieving an objective response. More strikingly, 7.0% were classified as exceptional responders, proving that for some, the right genomic match can lead to an unexpected recovery even in heavily pretreated cases.
This precision strategy proved particularly vital for those with rare cancers, who represent 39.1% of the DRUP population. These patients typically face the fewest standard options and, according to the data, benefited equally from the genomics-guided approach as those with more common malignancies.
The High Stakes of Unstructured Off-Label Use
The push for a structured framework like DRUP stems from the inherent dangers of unregulated off-label prescribing. When drugs are used outside of clinical trials and without rigorous oversight, patients—already fragile from previous treatments—face significant risks of toxicity. In the DRUP study, 28.4% of patients experienced grade 3 or higher treatment-related adverse events (TRAEs), illustrating the narrow therapeutic window clinicians must navigate.
Beyond patient safety, the lack of a systematic framework creates systemic inequities and financial strain. High drug prices, inconsistent insurance reimbursement, and the immense cost of managing severe toxicities place a heavy burden on healthcare systems. Without a data-generating structure, many patients are left with uneven access to potentially life-saving medicines based on their physician’s willingness to accept a risk or their ability to afford the drug.
Structured initiatives—including DRUP, the Targeting Agent and Profiling Utilization Registry (TAPUR) in the U.S., and the Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)—aim to mitigate these risks. By granting controlled access to treatment and monitoring outcomes, these programs can identify “early signals” of activity. Crucially, they too identify when a drug is not working. For instance, clinicians showed strong interest in using single-agent inhibitors for the CDK4/6 pathway, but the DRUP cohorts revealed that efficacy was limited, protecting future patients from ineffective and potentially toxic strategies.
What Drives Success in Precision Matching?
Analysis of the DRUP data reveals that not all genomic targets are created equal. The highest-performing treatments shared a common thread: a strong biological rationale and existing clinical evidence of activity. This aligns with established classification systems like the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) and OncoKB, which rank alterations by how “actionable” they are.
Key findings on patient outcomes include:
- Target Prioritization: High-success targets included BRAF p.V600E, MSI-H, and TMB-H, which are now recognized as tumour-agnostic targets.
- Timing of Intervention: Patients with fewer prior lines of treatment consistently saw improved outcomes, suggesting that precision therapies may be more effective when administered earlier in the disease course.
- The Role of Histology: While the goal is often “tumour-agnostic” treatment, the data showed that tissue context still mattered for 23.5% of the tested drug-target subgroups, meaning the origin of the cancer cannot be entirely ignored.
| Trial/Analysis | Objective Response Rate (ORR) |
|---|---|
| DRUP (Precision Strategy) | 15.7% |
| NCI-MATCH | 10.3% |
| MyPathway | 23% |
| General Meta-analysis | 14% |
Barriers to Scaling and National Reimbursement
Translating a successful trial result into a standard of care remains a significant hurdle. Despite 14 cohorts meeting the predefined success criteria in DRUP, only one expansion cohort reached completion. This gap is driven by two primary factors: regulatory misalignment and the economics of the pharmaceutical industry.
First, the criteria for “success” in early-stage precision trials often clash with the standards required for national reimbursement. Many cohorts showed “stable disease” for 16 weeks, but post-hoc analysis revealed that only half of those patients sustained that stability beyond 24 weeks. Regulatory bodies, such as those using the PASKWIL-criteria or the ESMO-MCBS, typically require more durable signals—such as progression-free survival (PFS) of at least six months—before approving payment.
Second, the “patent cliff” poses a threat to patient access. In several instances, by the time a precision cohort proved a drug was effective for a new, rare subgroup, the drug’s patent had expired or market competition had increased. This often reduces pharmaceutical companies’ interest in funding the larger trials necessary for official label expansion, leaving patients without a clear path to access a drug that has already been proven to work for them.
The Path Toward International Collaboration
The rarity of certain cancers means that a single country, such as the Netherlands, may not have enough patients to complete a clinical cohort. To solve this, the DRUP model has served as a blueprint for a network of national trials across Europe, including ProTarget in Denmark, MEGALiT in Sweden, IMPRESS-Norway, and FINPROVE in Finland.
These efforts are now being unified under the PCM4EU (Personalised Cancer Medicine for all EU Citizens) and PRIME-ROSE consortia. By sharing protocols and aligning endpoints, these organizations hope to accelerate enrollment and validate findings while drugs are still within their commercial lifespan, ensuring that evidence-based success leads to actual patient access.
As the field evolves, the integration of more potent next-generation therapies and sophisticated decision-support tools is expected to widen the therapeutic window. However, the overarching lesson from the last nine years is clear: off-label precision medicine is a powerful tool, but it must remain confined to structured, data-generating frameworks to ensure patient safety and scientific integrity.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Patients should consult with their healthcare provider regarding treatment options.
The next phase of this effort involves the continued rollout of the PCM4EU and PRIME-ROSE consortia to standardize precision oncology across the European Union. We invite readers to share their perspectives on precision medicine and the challenges of drug access in the comments below.
